What are the possible adverse reactions to ferrelectit (ferrous iron) and how should they be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Adverse Reactions to Ferrlecit (Sodium Ferric Gluconate)

Ferrlecit causes adverse reactions in approximately 10-35% of patients, with the most common being gastrointestinal symptoms (nausea, vomiting, diarrhea in 35%), hypotension (29%), injection site reactions (33%), and cramps (25%), but true anaphylaxis is extremely rare (<0.5%). 1

Most Common Adverse Reactions

In Adults (≥10% incidence):

  • Gastrointestinal: Nausea, vomiting, and/or diarrhea (35%)
  • Injection site reactions (33%)
  • Hypotension (29%)
  • Cramps (25%)
  • Hypertension (13%)
  • Dizziness (13%)
  • Abnormal erythrocytes (11%)
  • Dyspnea (11%)
  • Leg cramps (10%)
  • Chest pain (10%) 1

In Pediatric Patients (6-15 years, ≥10% incidence):

  • Hypotension (35%)
  • Headache (24%)
  • Hypertension (23%)
  • Tachycardia (17%)
  • Vomiting (11%) 1

Critical Safety Considerations

Hypersensitivity Reactions

The vast majority of reactions to intravenous iron are complement activation-related pseudo-allergy (CARPA/infusion reactions), NOT true IgE-mediated anaphylaxis. 2 True anaphylaxis occurs in approximately 0.5% of cases 3, though serious reactions have been reported including shock, loss of consciousness, and acute myocardial ischemia 1.

Dose-Related Risk

Individual doses exceeding 125 mg may be associated with higher incidence and/or severity of adverse events, including hypotension, nausea, vomiting, abdominal pain, diarrhea, dizziness, dyspnea, urticaria, chest pain, paresthesia, and peripheral swelling 1.

Hypophosphatemia

While hypophosphatemia is less common with ferric gluconate compared to ferric carboxymaltose (1% vs 58%), it can still occur with all parenteral iron preparations 3.

Management Algorithm

Pre-Administration Assessment:

  1. Question patients about prior reactions to ANY parenteral iron product 1
  2. Screen for major risk factors:
    • Previous reaction to iron infusion
    • Multiple drug allergies
    • Severe atopy
    • Systemic inflammatory diseases
    • Concomitant ACE inhibitor use (1.6% vs 0.7% reaction rate) 1
  3. Contraindications: Early pregnancy, ongoing bacteremia 3, 1

During Infusion:

  • Administer over 1 hour (standard protocol) 1
  • Meticulous observation required throughout infusion 4
  • Have emergency equipment immediately available

If Reaction Occurs:

For Mild-Moderate Infusion Reactions (most common):

  • Stop infusion immediately
  • Administer antihistamines (pheniramine maleate)
  • Consider corticosteroids
  • Provide supportive care (oxygen, IV fluids) 5
  • Most reactions resolve rapidly with drug withdrawal 1

For Severe Hypersensitivity/Anaphylaxis:

  • Stop infusion immediately
  • Administer epinephrine (first-line treatment)
  • Corticosteroids
  • Aggressive supportive care 6
  • Do not rechallenge with same formulation

Special Populations

Pregnancy:

Hypersensitivity reactions may cause fetal bradycardia—counsel pregnant women about this risk. Ferrlecit contains benzyl alcohol, which is rapidly metabolized by pregnant women but has caused adverse reactions in premature neonates 1.

Lactation:

Treatment with Ferrlecit is not recommended while breastfeeding 1.

Concomitant ACE Inhibitor Use:

Patients on ACE inhibitors have approximately 2-fold higher risk of reactions (1.6% vs 0.7%) 1.

Key Clinical Pitfalls

  1. Do not assume all reactions are true allergies—most are CARPA reactions that may not recur with slower infusion or different formulation 2, 4

  2. Previous reaction to iron dextran does NOT preclude use of ferric gluconate—case series demonstrate safe administration in patients with severe iron dextran reactions 7

  3. Infection is NOT an absolute contraindication—withhold only in active bacteremia; studies show no significant increase in clinically important infections 3

  4. Drug interaction: Ferrlecit reduces absorption of oral iron—do not co-administer 1

  5. Higher doses (>125 mg) carry increased risk—consider splitting doses if total requirement exceeds this threshold 1

Related Questions

After a hypersensitivity reaction to ferric maltose presenting with dizziness, infusion‑site pain, and toe pain that has been stabilized, should the patient be transferred to the emergency department from the infusion clinic?
My relative experienced hives after an intravenous iron infusion; is it safe for me to receive an iron infusion?
For a 39‑year‑old woman who experienced a mild reaction within two minutes of a ferric carboxymaltose (Ferrinject) infusion, what alternative intravenous iron preparations can be considered?
What is the most tolerable intravenous iron regimen for patients with known sensitivity or prior reactions to IV iron?
In a patient unable to tolerate oral iron who requires intravenous ferric carboxymaltose, which vitamins and minerals can be given concurrently and which should be avoided?
What medication should be prescribed instead of pramoxine for perianal pain or itching?
In a veteran aviation mechanic/crew chief (MOS 67U/15U) and aviation maintenance officer (151A) who repeatedly climbed and descended CH‑47/UH‑1 helicopters, is the development of a posterior calcaneal (Haglund’s) spur and the need for retrocalcaneal bursectomy at least as likely as not related to his service duties?
How long should anticoagulation be continued after a first mild incidentally discovered pulmonary embolism?
Is risperidone appropriate for treating substance cravings?
Which antiarrhythmic agents are contraindicated in patients with structural heart disease (e.g., prior myocardial infarction, left ventricular systolic dysfunction, cardiomyopathy, significant left ventricular hypertrophy, or valvular disease)?
Is severe patellofemoral compartment disease a form of osteoarthritis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.